Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Occupational exposures and asthma–COPD overlap in a clinical cohort of adult-onset asthma

Minna Tommola, Pinja Ilmarinen, Leena E. Tuomisto, Lauri Lehtimäki, Hannu Kankaanranta
ERJ Open Research 2019 5: 00191-2019; DOI: 10.1183/23120541.00191-2019
Minna Tommola
1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
2Dept of Respiratory Medicine, Central Finland Central Hospital, Jyväskylä, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Minna Tommola
  • For correspondence: minna.tommola@ksshp.fi
Pinja Ilmarinen
1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leena E. Tuomisto
1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leena E. Tuomisto
Lauri Lehtimäki
3Allergy Centre, Tampere University Hospital, Tampere, Finland
4Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lauri Lehtimäki
Hannu Kankaanranta
1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
4Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hannu Kankaanranta
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Occupational exposure to vapours, gases, dusts or fumes (VGDF) increases the prevalence of asthma–COPD overlap (ACO) in adult-onset asthma. VGDF exposure is independently associated with ACO and an additive effect with smoking is proposed. http://bit.ly/2LiMiXW

To the Editor:

Asthma–COPD overlap (ACO) has recently been recognised as a separate phenotype of obstructive airway diseases and is included in several guidelines of asthma and COPD [1–5]. ACO patients have previously been shown to have lower diffusing capacity of the lung, higher blood neutrophil counts and higher interleukin-6 levels compared with asthma patients [6]. In COPD, fixed airway obstruction is considered to develop in response to chronic exposure to noxious inhaled particles [7]. In western countries, the most common cause of COPD is tobacco smoking, but occupational exposure to dusts and fumes has also been shown to increase the risk for developing COPD [7, 8]. However, the role of occupational exposures in the development of ACO is not known.

We studied the association between ACO and occupational exposures to vapours, gases, dusts or fumes (VGDF) in the cohort of the Seinäjoki Adult Asthma Study (SAAS). In the SAAS, 257 patients were diagnosed with new-onset asthma at adult age and followed for 12 years. Diagnosis was made by a respiratory physician and based on objective lung function measurements and medical history [6, 9–12]. Ex- and current smokers were included, and the smoking history of every patient was carefully assessed. After 12 years (years 2012–2013), patients had a control visit, and the occupational data were retrospectively collected. To evaluate the duration of the patients' occupation, the occupation at the time of asthma diagnosis was confirmed from patient records. Patients with detailed smoking history available (n=194) at the follow-up visit were included in the current study. Patients were considered as ACO patients if they had a ≥10-pack-year history of smoking and post-bronchodilation forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 at the follow-up visit. The subjects were divided into two groups based on whether they had occupational exposure history to VGDF (i.e. welders, foundry workers, sheet metal workers, smiths, machine workshop workers, mechanics and farmers).

The prevalence of ACO was higher in the group with occupational VGDF exposure, compared to patients with no exposure. Patients with occupational VGDF exposure were older and more often males. A tendency towards higher body mass index (BMI) in patients with occupational VGDF exposure was seen. No differences in the prevalence of allergic conditions or in the use of daily inhaled corticosteroids were seen between the groups (table 1). No statistically significant differences in the rate of airway obstruction at the time of diagnosis were seen between the groups, although a tendency towards more severe obstruction among patients with occupational VGDF exposure was observed: post-bronchodilation FEV1/FVC (95% CI) was 0.77 (0.72–0.81) among patients with occupational VGDF exposure, and 0.79 (0.75–0.84) in patients with no VGDF exposure (p=0.060).

View this table:
  • View inline
  • View popup
TABLE 1

Clinical characteristics and prevalence of asthma–COPD overlap in groups of different occupational exposure to vapours, gases, dusts or fumes (VGDF)

The mean±sd smoking history of the ACO patients did not differ between the groups: 27.4±13.0 pack-years in ACO patients with no occupational VGDF exposure, and 27.4±17.4 pack-years in ACO patients with VGDF exposure (p=0.992). The prevalence of obstructive asthma was similar between the groups, i.e. asthma patients with low smoking history (<10 pack-years) but fixed airway obstruction (post-bronchodilation FEV1/FVC <0.7) (table 1).

We further analysed the factors associated with airway obstruction and ACO with two multivariable logistic regression analyses: 1) with a regression model among all patients (n=194), we analysed the factors associated with airway obstruction (i.e. FEV1/FVC <0.7); and 2) with a regression model among patients with ≥10 pack-years of smoking history (n=65), we analysed the factors associated with ACO. Among all patients, the number of pack-years (OR 1.05, 95% CI 1.02–1.08; p<0.001) and age (OR 1.04, 95% CI 1.01–1.07; p=0.008) were significantly associated with airway obstruction, whereas BMI ≥30 kg·m−2 was associated with lower risk of obstruction (OR 0.37, 95% CI 0.16–0.85; p=0.019). Sex or occupational VGDF exposure were not associated with obstruction. Among patients with ≥10 pack-years of smoking, a significant factor associated with ACO was occupational VGDF exposure (OR 4.2, 95% CI 1.1–15.3; p=0.030), whereas BMI ≥30 kg·m−2 was associated with lower risk of ACO (OR 0.18, 95% CI 0.06–0.59; p=0.004). The number of pack-years was not associated with ACO among patients with smoking history ≥10 pack-years (OR 1.02, 95% CI 0.98–1.07; p=0.281). Sex, age or smoking status (never-/ex-/current smoker) were not significantly associated with ACO as analysed by backward, forward or enter methods and, thus, were not included in the final model.

Our results suggest that adult-onset asthma patients with occupational exposure to VGDF more often develop ACO, compared with patients with no such exposure. The smoking history of ACO patients was similar, regardless of their exposure to VGDF, suggesting that heavier smoking is not the reason for increased ACO prevalence in the group with occupational VGDF exposure in our study. In addition, the proportion of patients with smoking history ≥10 pack-years did not differ between the groups. The patients with occupational VGDF exposure were older than patients without. However, the rate of airway obstruction at the time of asthma diagnosis was not significantly different between the groups. Thus, the increased ACO rate in the group of occupational VGDF exposure is not merely explained by inferior lung function at the diagnosis. Furthermore, when we evaluated the prevalence of non- or low-smoking patients (<10 pack-years) with fixed airway obstruction (i.e. obstructive asthma), we found no differences between the groups. This finding suggests that, in adult-onset asthma, occupational exposure alone is not driving the risk of ACO but rather the combination of occupational exposure and smoking. This is in keeping with the previous suggestions of the additive effect of smoking and other environmental exposures in the development of COPD [13]. Furthermore, the multivariable regression analyses showed that occupational VGDF exposure was independently associated with ACO among patients with ≥10 pack-years of smoking history. In contrast, obesity seemed to lower the risk of ACO. This finding might be explained by reduction of FVC in obese patients, leading to decreased sensitivity of FEV1/FVC ratio in detecting obstruction [14]. Although patients in the group with occupational exposures were older and more often males, age and sex were not associated with ACO.

In the current study, 17% (n=33) reported farming as their main profession, and when metal workers were also assessed, up to 23% (n=44) were considered as working in a profession linked to increased risk of developing COPD. This gives us a good view of work-related ACO in real-life asthma patients. Furthermore, the diagnosis of asthma was based on objective lung function measurements, and diagnostic guidelines were carefully followed. The quantity of exposure to occupational particles was not measured, which could be considered as a limitation of the current study. However, the reported occupational information was confirmed from patient records, showing stability of profession during the 12 years of follow-up on nearly all patients. We also recognise the possibility of occupational exposures in other professions (e.g. cleaners, waiters). However, considering the current knowledge of occupational exposures, we assessed the professions that are presumed to have the highest exposure related to development of fixed airway obstruction.

Taken together, our results show increased prevalence of ACO in the group of adult-onset asthma patients with occupational VGDF exposure. This is a new finding and in line with what is known on the additive effect of smoking and occupational exposure in the development of fixed airways obstruction and COPD. We thus support active intervention in primary and occupational healthcare, aiming towards smoking cessation and protection against occupational noxious particles in the air.

Acknowledgements

We are grateful to Aino Sepponen (Seinäjoki Central Hospital, Seinäjoki, Finland) for her input with data management.

Footnotes

  • This study is registered at www.ClinicalTrials.gov with identifier number NCT02733016.

  • Author contributions: M. Tommola, P. Ilmarinen, L.E. Tuomisto, L. Lehtimäki and H. Kankaanranta designed the study and wrote the report. M. Tommola, P. Ilmarinen and H. Kankaanranta performed the statistical analyses. All authors contributed to interpretation of the data. All authors made critical revisions of the manuscript and approved the final version of the manuscript.

  • Conflict of interest: M. Tommola reports personal fees for lectures from AstraZeneca, Filha ry, GlaxoSmithKline, Pfizer and Chiesi, personal fees for lectures and consultation from Boehringer Ingelheim, and grants from the Orion Research Foundation, outside the submitted work.

  • Conflict of interest: P. Ilmarinen reports grants from AstraZeneca, and payment for lectures from Mundipharma, Orion and AstraZeneca, outside the submitted work.

  • Conflict of interest: L.E. Tuomisto reports compensation of costs for attending an international congress from Chiesi, Orion Pharma and Teva, for attending an international congress and costs for lectures from Boehringer Ingelheim, and for lectures from AstraZeneca, outside the submitted work.

  • Conflict of interest: L. Lehtimäki reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, Orion Pharma, Teva and ALK, outside the submitted work.

  • Conflict of interest: H. Kankaanranta reports grants from AstraZeneca, during the conduct of the study; as well as personal fees and non-financial support from AstraZeneca and Boehringer Ingelheim, personal fees from Chiesi Pharma AB, GlaxoSmithKline, Leiras-Takeda, MSD, Novartis, Mundipharma, Roche, Sanofi Genzyme and Orion Pharma, and non-financial support from Intermune, all outside the submitted work.

  • Support statement: Supported by Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation (Helsinki, Finland), the Research Foundation of the Pulmonary Diseases (Helsinki, Finland), Orion Research Foundation (Espoo, Finland), the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland) and the Medical Research Fund of Seinäjoki Central Hospital (Seinäjoki, Finland). None of the sponsors had any involvement in the planning, execution, drafting or write-up of this study. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received August 2, 2019.
  • Accepted August 25, 2019.
  • Copyright ©ERS 2019
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    Global Initiative for Asthma, Global Initiative for Chronic Obstructive Lung Disease. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma–COPD Overlap Syndrome (ACOS). 2015. Available from: www.ginasthma.org Date last accessed: 2 May 2016.
    1. Kankaanranta H,
    2. Harju T,
    3. Kilpeläinen M, et al.
    Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the Finnish guidelines. Basic Clin Pharmacol Toxicol 2015; 116: 291–307.
    OpenUrlCrossRefPubMed
    1. Miravitlles M,
    2. Soler-Cataluña JJ,
    3. Calle M, et al.
    A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J 2013; 22: 117–121.
    OpenUrlCrossRefPubMed
    1. Postma DS,
    2. Rabe KF
    . The asthma–COPD overlap syndrome. N Engl J Med 2015; 373: 1241–1249.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Miravitlles M,
    2. Vogelmeier C,
    3. Roche N, et al.
    A review of national guidelines for management of COPD in Europe. Eur Respir J 2016; 47: 625–637.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Tommola M,
    2. Ilmarinen P,
    3. Tuomisto LE, et al.
    Differences between asthma–COPD overlap syndrome and adult-onset asthma. Eur Respir J 2017; 49: 1602383.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019 Report. Available from: http://goldcopd.org Date last accessed: 9 November 2018.
  5. ↵
    1. Sadhra S,
    2. Kurmi OP,
    3. Sadhra SS, et al.
    Occupational COPD and job exposure matrices: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2017; 12: 725–734.
    OpenUrl
  6. ↵
    1. Kankaanranta H,
    2. Ilmarinen P,
    3. Kankaanranta T, et al.
    Seinäjoki Adult Asthma Study (SAAS): a protocol for a 12-year real-life follow-up study of new-onset asthma diagnosed at adult age and treated in primary and specialised care. NPJ Prim Care Respir Med 2015; 25: 15042.
    OpenUrlCrossRefPubMed
    1. Ilmarinen P,
    2. Tuomisto LE,
    3. Niemelä O, et al.
    Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma. Eur Respir J 2016; 48: 1052–1062.
    OpenUrlAbstract/FREE Full Text
    1. Tuomisto LE,
    2. Ilmarinen P,
    3. Niemelä O, et al.
    A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study. Respir Med 2016; 117: 223–229.
    OpenUrl
  7. ↵
    1. Tommola M,
    2. Ilmarinen P,
    3. Tuomisto LE, et al.
    The effect of smoking on lung function: a clinical study of adult-onset asthma. Eur Respir J 2016; 48: 1298–1306.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Blanc PD,
    2. Iribarren C,
    3. Trupin L, et al.
    Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009; 64: 6–12.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. O'Donnell DE,
    2. Ciavaglia CE,
    3. Neder JA
    . When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences. Ann Am Thorac Soc 2014; 11: 635–644.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 5 Issue 4 Table of Contents
ERJ Open Research: 5 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Occupational exposures and asthma–COPD overlap in a clinical cohort of adult-onset asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Occupational exposures and asthma–COPD overlap in a clinical cohort of adult-onset asthma
Minna Tommola, Pinja Ilmarinen, Leena E. Tuomisto, Lauri Lehtimäki, Hannu Kankaanranta
ERJ Open Research Oct 2019, 5 (4) 00191-2019; DOI: 10.1183/23120541.00191-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Occupational exposures and asthma–COPD overlap in a clinical cohort of adult-onset asthma
Minna Tommola, Pinja Ilmarinen, Leena E. Tuomisto, Lauri Lehtimäki, Hannu Kankaanranta
ERJ Open Research Oct 2019, 5 (4) 00191-2019; DOI: 10.1183/23120541.00191-2019
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • rs2070600 SNP regulates AGER splicing and sputum sRAGE
  • Procoagulant microparticles and COVID-19
  • Cancer referral and interventional pulmonology during COVID-19
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society